What the future holds: BBT-176, beyond third-generation EGFR tyrosine kinase inhibitors

Transl Lung Cancer Res. 2024 Feb 29;13(2):220-222. doi: 10.21037/tlcr-23-795. Epub 2024 Feb 27.
No abstract available

Keywords: BBT-176; Tyrosine kinase inhibitors (TKIs); epidermal growth factor receptor (EGFR); non-small cell lung cancer (NSCLC); osimertinib.

Publication types

  • Editorial
  • Comment